turalio pexidartinib hydrochloride 125 mg

1 INDICATIONS AND USAGE TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. ( 1 )

daiichi sankyo, inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] pain` `[3] fatigue` `[4] nausea` `[5] headache` `[6] dyspnoea` `[7] vomiting` `[8] arthralgia` `[9] breast cancer female` `[10] off label use`

2 years ago

CAPSULE BLUE DSC521

16 HOW SUPPLIED/STORAGE AND HANDLING TURALIO 125 mg capsules are supplied as size 1 with white opaque body and powder blue opaque cap with black print "DSC521", available in: 28 count bottle 120 count bottle NDC#: 65597-407-28 NDC#: 65597-407-20 Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep containers closed and do not remove desiccant from bottles.

More pills like CAPSULE DSC521

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

turalio pexidartinib hydrochloride 125 mg

FDA Reported Adverse Reactions [1] drug ineffective [2] pain [3] fatigue [4] nausea [5] headache [6] dyspnoea [7] vomiting [8] arthralgia [9] breast cancer female [10] off label use

CAPSULE BLUE DSC521

More pills like CAPSULE DSC521

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] pain` `[3] fatigue` `[4] nausea` `[5] headache` `[6] dyspnoea` `[7] vomiting` `[8] arthralgia` `[9] breast cancer female` `[10] off label use`